null

SMILES Cc1cc(C)c2[nH]ccc2c1CN1CCCCC1c1ccc(cc1)C(O)=O

InChI Key

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 160473   

TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 15nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2XG9P9JUS Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 1.50E+4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6T75US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 47nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6T75US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research

Curated by ChEMBL
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human ERG by radioligand binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetAlpha-1A adrenergic receptor(Homo sapiens (Human))
Novartis Institutes for BioMedical Research

Curated by ChEMBL
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of adrenergic receptor alpha1a (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetComplement factor B(Mus musculus)
Novartis Institutes for BioMedical Research

Curated by ChEMBL
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 2.28E+3nMAssay Description:Inhibition of serine protease factor B in 50% mouse serum assessed as reduction in C3b deposition pre-incubated for 15 mins before activated zymosan ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 62nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 62nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 1.70E+4nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 250nMAssay Description:Inhibition of serine protease factor B in 50% human whole blood assessed as reduction in alternative pathway-mediated membrane attack complex formati...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed
TargetAlpha-2C adrenergic receptor(Homo sapiens (Human))
Novartis Institutes for BioMedical Research

Curated by ChEMBL
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)copy SMILES
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of adrenergic receptor alpha2c (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q21N84P4PubMed